Lipid lowering therapy Articles

Articles
Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials
Xie S, Galimberti F, Olmastroni E, et al.
Journal:
Cardiovasc Res

First published: February 19, 2024 DOI: 10.1093/cvr/cvae034
View
- Share
Articles
Assessing the Role of Bempedoic Acid in Lipid-Lowering Therapy
Fernandez-Vazquez D, Weideman S, Banerjee S
Journal:
Am J Cardiol

First published: February 16, 2024 DOI: 10.1016/j.amjcard.2024.02.002
View
- Share
Articles
Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bétrisey S, Haller ML, Efthimiou O, et al.
Journal:
J Am Heart Assoc

First published: February 7, 2024 DOI: 10.1161/JAHA.123.030714
View
- Share
Articles
LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes
Santos RD, Cuchel M
Journal:
Circulation

First published: January 29, 2024 DOI: 10.1161/CIRCULATIONAHA.123.067241
View
- Share
Articles
World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update
Laranjo L, Lanas F, Sun MC, et al.
Journal:
Glob Heart

First published: January 22, 2024 DOI: 10.5334/gh.1278
View
- Share
Articles
Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering
Norata GD, Tokgözoğlu L
Journal:
Eur Heart J

First published: November 8, 2023 DOI: 10.1093/eurheartj/ehad682
View
- Share
Articles
2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
Banach M, Surma S, Toth PP; endorsed by the International Lipid Expert Panel (ILEP)
Journal:
Arch Med Sci

First published: November 2, 2023 DOI: 10.5114/aoms/174743
View
- Share
Articles
Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry
Kayıkcioglu M, Başaran Ö, Doğan V, et al.
Journal:
J Clin Lipidol

First published: November 1, 2023 DOI: 10.1016/j.jacl.2023.09.013
View
- Share
Articles
LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals
Andersson NW, Corn G, Dohlmann TL, et al.
Journal:
J Am Coll Cardiol

First published: October 3, 2023 DOI: 10.1016/j.jacc.2023.07.027
View
- Share
Articles
First clinical experiences with inclisiran in a real-world setting
Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE
Journal:
J Clin Lipidol

First published: September 18, 2023 DOI: 10.1016/j.jacl.2023.09.005
View
- Share
Articles
Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients
Toplak H, Bilitou A, Alber H, et al.
Journal:
Wien Klin Wochenschr

First published: June 8, 2023 DOI: 10.1007/s00508-023-02221-4
View
- Share

Lipid lowering therapy Articles

Articles

Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials

Xie S, Galimberti F, Olmastroni E, et al.

Articles

Assessing the Role of Bempedoic Acid in Lipid-Lowering Therapy

Fernandez-Vazquez D, Weideman S, Banerjee S

Articles

Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bétrisey S, Haller ML, Efthimiou O, et al.

Articles

LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes

Santos RD, Cuchel M

Articles

World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update

Laranjo L, Lanas F, Sun MC, et al.

Articles

Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering

Norata GD, Tokgözoğlu L

Articles

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

Banach M, Surma S, Toth PP; endorsed by the International Lipid Expert Panel (ILEP)

Articles

Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry

Kayıkcioglu M, Başaran Ö, Doğan V, et al.

Articles

LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals

Andersson NW, Corn G, Dohlmann TL, et al.

Articles

First clinical experiences with inclisiran in a real-world setting

Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE

Articles

Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients

Toplak H, Bilitou A, Alber H, et al.

Articles

Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials

Xie S, Galimberti F, Olmastroni E, et al.

Share

Articles

Assessing the Role of Bempedoic Acid in Lipid-Lowering Therapy

Fernandez-Vazquez D, Weideman S, Banerjee S

Share

Articles

Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bétrisey S, Haller ML, Efthimiou O, et al.

Share

Articles

LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes

Santos RD, Cuchel M

Share

Articles

World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update

Laranjo L, Lanas F, Sun MC, et al.

Share

Articles

Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering

Norata GD, Tokgözoğlu L

Share

Articles

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

Banach M, Surma S, Toth PP; endorsed by the International Lipid Expert Panel (ILEP)

Share

Articles

Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry

Kayıkcioglu M, Başaran Ö, Doğan V, et al.

Share

Articles

LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals

Andersson NW, Corn G, Dohlmann TL, et al.

Share

Articles

First clinical experiences with inclisiran in a real-world setting

Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE

Share

Articles

Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients

Toplak H, Bilitou A, Alber H, et al.

Share